Turning severe into moderate haemophilia by prophylaxis: Are we reaching our goal?

Blood Transfusion

Volumn 11, Issue 3, 2013, Pages 364-369

  Den Uijl, Ingrid ^a,b   Biesma, Douwe ^c   Grobbee, Diederick ^b   Fischer, Kathelijn ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b General Practice   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Comparison; HJHS; Joint bleeding; Moderate haemophilia; Severe haemophilia

Indexed keywords

BLOOD CLOTTING FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMARTHROSIS; HEMOPHILIA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PROPHYLAXIS; QUALITY OF LIFE; SHORT FORM 36; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; HEMOPHILIA A; HEMORRHAGE; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADULT; CHILD; FEMALE; FOLLOW-UP STUDIES; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84882366280     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0092-12     Document Type: Article

References (16)

1. Pool JG. Cryoprecipitate in the treatment of hemophilia. Calif Med 1970; 113: 66-7.
2. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-35.
3. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16 (Suppl. 5): 181-8.
4. Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
5. Bjorkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: The influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010; 8: 730-6.
6. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-97.
7. Kreuz W, Escuriola EC, Funk M, et al. [Prevention of joint damage in hemophilic children with early prophylaxis]. Orthopade 1999; 28: 341-6.
8. Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
9. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381-95.
10. Koiter J, van Genderen FR, Brons PP, Nijhuis-van der Sanden MW. Participation and risk-taking behaviour in sports in children with haemophilia. Haemophilia 2009; 15: 686-94.
11. VanderZee KI, Sanderman R, Heyink JW, de HH. Psychometric qualities of the RAND 36-Item Health Survey 1.0: a multidimensional measure of general health status. Int J Behav Med 1996; 3: 104-22.
12. Stolk EA, Busschbach JJ. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res 2003; 12: 363-71.
13. Collins PW, Fischer K, Morfini M, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
14. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20. Arrived: 28 April 2012 - Revision accepted: 18 July 2012.
15. De MP, Urbancik W, van den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14: 931-8.
16. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twentyfive years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.